MarkDanielPegramMD

Oncology • Stanford, CA

Professor, Medicine, Stanford University Sch of Med

Join to view full profile

Are you Dr. Pegram?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 69 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
300 Pasteur Dr
Fl 1
Stanford, CA 94305
Phone+1 650-723-4000

Summary

Dr. Mark Pegram, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California, Florida, and Texas. He is affiliated with Stanford Health Care and is a Professor at Stanford University Sch of Med.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1986 - 1989
University of North Carolina at Chapel Hill School of MedicineClass of 1986

Certifications & Licensure

CA State Medical License 1989 - 2026
FL State Medical License 2008 - 2012
TX State Medical License 1989 - 1990
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2007, 2010-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer Start of enrollment: 2001 Dec 01
Unknown status
Phase 1, Phase 2
Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2003 May 01
Unknown status
Phase 1, Phase 2
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu Start of enrollment: 2004 Mar 01
Completed
Phase 1
BMS-599626 in Treating Patients With Metastatic Solid Tumors Start of enrollment: 2004 Aug 01
Completed
Phase 1
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) Start of enrollment: 2003 Jun 01
Completed
Phase 1, Phase 2
Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2004 May 01
Completed
Phase 1
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2004 Dec 01
Completed
Phase 2
PR-104 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2005 Dec 01
Completed
Phase 1
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors Start of enrollment: 2005 Aug 01
Completed
Not Applicable
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Start of enrollment: 2008 Oct 21
Completed
Phase 1, Phase 2
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 2
Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer Start of enrollment: 2013 Dec 01
Terminated
Phase 1, Phase 2
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors. Start of enrollment: 2015 Sep 23
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

7612 citations
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon, Brian Leyland-Jones, Steven Shak, Hank Fuchs, Virginia E. Paton
The New England Journal of Medicine. 2001-03-15
59 citations
Role of Fcγ receptors in HER2-targeted breast cancer therapy.
Antonino Musolino, William J Gradishar, Hope S Rugo, Jeffrey L Nordstrom, Edwin P Rock
Journal for Immunotherapy of Cancer. 2022-01-01
8235 citations
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt, Robert S. Fulton, Michael D. McLellan, Heather Schmidt, Joelle Kalicki-Veizer
Nature. 2012-10-04

Press Mentions

Meet 7 Femtech Companies Innovating in the Area of Ovarian Health, Breast and Gynecological CancersMarch 16th, 2022
Clinical Picture Brightens for HER2+ Breast Cancer with Brain MetastasesMarch 7th, 2022
Cedars-Sinai, Rubedo Partner to Develop Targeted IPF TreatmentsJune 8th, 2021
Join now to see all